Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.63 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 11/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.46 |
| ▸ | NPY1R | P25929 | 8/20 | 0.46 |
| ▸ | NPY2R | P49146 | 5/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463273 | 0.96 | SIRT5 (0.59) | SIRT5FOLH1NPY4RNPY5RNPY1R | |
| SCHEMBL13166808 | 0.96 | SIRT5 (0.59) | SIRT5FOLH1NPY4RNPY5RNPY1R | |
| SCHEMBL13701342 | 0.95 | SIRT5 (0.57) | SIRT5FOLH1NPY4RNPY5RNPY1R | |
| SCHEMBL12035334 | 0.93 | SIRT5 (0.55) | SIRT5FOLH1NPY4RNPY5RNPY1R | |
| SCHEMBL13624779 | 0.93 | FOLH1 (0.55) | SIRT5FOLH1NPY4RNPY5RNPY1R | |
| SCHEMBL30248962 | 0.93 | FOLH1 (0.55) | SIRT5FOLH1NPY4RNPY5RNPY1R | |
| SCHEMBL31157697 | 0.92 | SIRT5 (0.55) | SIRT5FOLH1NPY4RNPY5RNPY1R | |
| SCHEMBL28459707 | 0.92 | SIRT5 (0.55) | SIRT5FOLH1NPY4RNPY5RNPY1R | |
| SCHEMBL13166806 | 0.92 | SIRT5 (0.55) | SIRT5FOLH1NPY4RNPY5RNPY1R | |
| SCHEMBL28645337 | 0.92 | SIRT5 (0.55) | SIRT5FOLH1NPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221513-A1 | Treatment of Neurodegenerative Disorders | THE OPEN UNIVERSITY (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221513-A1 | Treatment of Neurodegenerative Disorders | THE OPEN UNIVERSITY (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221513-A1 | Treatment of Neurodegenerative Disorders | ARGLU1, GRN, NLN | SIRT5 3926/4885FOLH1 449/4885NPY4R 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.